潘妥拉唑
潘妥拉唑 (Pantoprazole) 是一種強效的**質子幫浦抑制劑 (PPI)**，用於治療和預防與胃酸相關的病理情況，如胃潰瘍、糜爛性食道炎和壓力性黏膜疾病。 雖然**奧美拉唑 (Omeprazole)** 是獸醫學中最廣泛使用的口服 PPI，但潘妥拉唑因其**靜脈注射 (IV) 劑型**而在臨床實務中備受重視。這使其成為無法耐受口服藥物或胃腸道吸收受損的住院重症病患（例如患有嚴重胰臟炎、小病毒性腸炎或活動性胃腸道出血的犬貓）的絕佳選擇。 * **臨床要點：** 儘管其血漿半衰期非常短（約 1 小時），但由於其在受體位點的不可逆結合，其臨床效果可持續 24 小時或更長時間。 * 研究顯示它能直接減少體外*幽門螺旋桿菌*的數量，並被用於某些根除治療方案中。
作用機制: Pantoprazole is a substituted benzimidazole weak base. It accumulates in the highly acidic environment of the gastric parietal cell secretory canaliculi, where it is protonated and converted into its active sulfenamide form. * **Mechanism:** The active form binds **irreversibly via covalent disulfide bonds** to the **H+/K+ ATPase enzyme system** (the "proton pump") at the secretory surface of gastric parietal cells. * **Pathway:** Systemic circulation → Parietal cell → Acidic canaliculi → Active sulfenamide → **Irreversible inhibition of H+/K+ ATPase** → Profound suppression of both basal and stimulated gastric acid secretion. Because the binding is irreversible, acid secretion only resumes when new proton pump enzymes are synthesized by the parietal cell, explaining the prolonged duration of action despite rapid systemic clearance.
各物種劑量
- Gastric acid suppression · 0.5-1 mg/kg · IV · q24h · Administer over 15 minutes
- All uses (ulcers, oesophagitis, hypersecretory conditions) · 0.7-1.0 mg/kg · IV · q24h · Not specified · Administer over 15 min. Oral dose not established but likely similar to IV dose.
- Gastric acid suppression in neonatal foals · 1.5 mg/kg · IV · once daily · From an experimental study evaluating normal neonatal foals. Further studies required for critically ill patients.
- Intravenous treatment of stress-related mucosal disease · 0.7-1 mg/kg · IV · once daily
- Gastric acid suppression · 0.5-1 mg/kg · IV · q24h · Administer over 15 minutes
- All uses (ulcers, oesophagitis, hypersecretory conditions) · 0.7-1.0 mg/kg · IV · q24h · Not specified · Administer over 15 min. Oral dose not established but likely similar to IV dose.
劑量為合格獸醫專業人員的臨床參考。請務必對照最新藥品仿單及個別病患確認。
給藥途徑
禁忌症
- Known hypersensitivity to pantoprazole or other substituted benzimidazole PPIs
- Intramuscular (IM) or Subcutaneous (SQ) administration (parenteral form must be given IV)
- Intramuscular (IM) administration
- Subcutaneous (SC) administration
不良反應
- Diarrhea
- Headache (reported in humans)
- Hyperglycemia (rare, ~1% in humans)
- Injection site reactions (thrombophlebitis, abscess) with IV use
- Potential increased risk of community-acquired pneumonia (noted in human literature)
- Diarrhoea
- Headache
- Hyperglycaemia (rare)
- Increased risk of pneumonia
- Thrombophlebitis (associated with IV injection)
藥物相互作用
- Ketoconazole, itraconazole, iron, ampicillin esters · Decreased drug absorption due to increased gastric pH (these drugs require an acidic environment for optimal absorption)
- Sucralfate · May decrease the bioavailability of orally administered pantoprazole
- Warfarin · Pantoprazole may increase the anticoagulant effect
- Itraconazole · Decreased absorption of itraconazole due to increased gastric pH · moderate
- Ketoconazole · Decreased absorption of ketoconazole due to increased gastric pH · moderate
監測
- Efficacy (resolution of clinical signs, improvement in gastric pH)
- Adverse effects (vomiting, diarrhea)
- Injection site reactions (thrombophlebitis, abscess) if used IV
- Resolution of clinical signs (vomiting, melena, regurgitation)
- Gastric pH (in critical care settings)
- IV catheter site for signs of thrombophlebitis
過量
Limited information available in veterinary species. A single oral dose of 887 mg/kg was lethal in dogs, causing acute toxic signs including ataxia, hypo-activity, and tremor. In humans, single oral overdoses up to 600 mg have been reported without adversity. In the event of a large overdose, contact an animal poison control center for guidance.
VetSheet 藥物參考供持牌獸醫專業人員作臨床決策輔助之用,不能取代專業判斷或廠方最新藥品說明書。